Daclizumab for relapsing remitting multiple sclerosis
Referencias
Additional references
Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Daclizumab in treatment of multiple sclerosis patients. Multiple Sclerosis 2009;15(2):272‐4.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):577‐60.
Kaufman DM. Safe administration and monitoring of monoclonal antibodies in the treatment of multiple sclerosis. Supplement to the International Journal of MS Care 2007;Suppl. 2:4‐21.
Killestein J, Polman C, Uitdehaag BMJ. Cannabinoids for multiple sclerosis. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003981]
Lefebrvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of neurology 2001;50(1):121‐7.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald' criteria. Annals of Neurology 2005;58:840‐6.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of neurology 1983;13(3):227‐31.
The Nordic Cochrane Centre, TheCochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, TheCochrane Collaboration, 2008.
Schippling DS, Martin R. Spotlight on anti‐CD25: daclizumab in MS. International MS Journal 2008;15(3):94‐8.
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 (PT1):133‐46.
